bpc - 157 | Gastric Pentadecapeptide BPC-157: Experimental Peptide Creates Risk

These beneficial effects of BPC 157 therapy [152,153,154,155] contrast with the use of agents that particularly promote epithelial growth, a widely acknowledged fear of inappropriate levels of proliferation, or, potentially carcinomatous changes, either within the gastrointestinal tract or elsewhere [156]

In the United States, the FDA did not approve the agent because of its association with a risk of psychiatric disorders including depression and suicidal tendencies [27]

The Role of Peptides in Physical Performance

Commercial oral supplements likely deliver negligible active peptide despite marketing claims

For patients on BPC-157 for joint inflammation, the second and third month often mark the point where the inflammatory pattern breaks rather than just being suppressed